The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1279 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-17

Study Completion Date

2021-04-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ECLA PHRI COLCOVID Trial is a simple, pragmatic randomized open controlled trial to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality and/or new requirement for mechanical ventilation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Colchicine in Hospitalized Colombian Patients With COVID-19

NCT04539873

Corona Virus Infection

TERMINATED PHASE3

Trial to Study the Benefit of Colchicine in Patients With COVID-19

NCT04350320

COVID19

COMPLETED PHASE3

Colchicine in Patients With Mild and Severe Coronavirus Disease

NCT04367168

COVID

TERMINATED PHASE2

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

NCT04322682

Corona Virus Infection

TERMINATED PHASE3

Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19

NCT04997551

COVID-19 Infection

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Various anti-viral treatments are being tested in clinical trials worldwide. The World Health Organization (WHO) launched a simple,pragmatic worldwide open-label trial to test Remdesivir, Lopinavir/Ritonavir, Interferon and Hydroxychloroquine or Chloroquine.The most important complication of COVID-19 severe cases is respiratory failure from severe acute respiratory syndrome (SARS), the leading cause of mortality. Accumulating evidence suggests that patients with severe COVID-19 might have a cytokine storm syndrome, a hyperinflammatory syndrome characterized by a fulminant and fatal hypercytokinemia and multiorgan failure.

The proposed pathophysiological mechanism of cytokine storm and inflammatory cascade activation is based on evidence collected primarily during the SARS-CoV and MERS-CoV epidemics (with a significant increase in IL1B, IL6, IL12, IFNγ, IP10, TNFα, IL15, and IL17 among others). The data collected during the pandemic with COVID-19 also shows a significant increase in inflammatory cytokines (GCSF, IP10, MCP1, MIP1A, and TNFα, among others) in sicker patients admitted to intensive care. In the absence of effective treatments for the management of patients with COVID-19 and respiratory failure, the immunomodulatory and anti-inflammatory effect of colchicine on cytokines involved in the hyper-inflammatory state is postulated. Several lines of research worldwide are testing powerful anti-inflammatory drugs for the pandemic, with different options including steroids, cytokine blockers, and other potent anti-inflammatory agents. Steroids are partially contraindicated in viral infections.

Colchicine is a powerful anti-inflammatory drug approved for the treatment or prevention of gout and Familial Mediterranean Fever at doses ranging between 0.3 mg and 2.4 mg/day. Its mechanism of action is through the inhibition of tubulin polymerization, as well as through potential effects on cellular adhesion molecules and inflammatory chemokines. It might also have direct anti-inflammatory effects by inhibiting key inflammatory signalling networks known as inflammasome and pro-inflammatory cytokines. Additionally, evidence suggests that colchicine exerts a direct anti-inflammatory effect by inhibiting the synthesis of tumor necrosis factor alpha and IL-6, monocyte migration, and the secretion of matrix metalloproteinase-9. Through the disruption of the cytoskeleton, colchicine is believed to suppress secretion of cytokines and chemokines as well as in vitro platelet aggregation. All these are potentially beneficial effects that might diminish or ameliorate the COVID-19 inflammatory storm associated with severe forms of the disease. Importantly, in one contemporary trial low-dose colchicine administered to patients who survived from acute coronary syndrome shows a statistically significantly reduction of cardiovascular complications.

We have therefore designed in a simple, pragmatic randomized controlled trial to test the effects of colchicine on severe hospitalized COVID-19 cases with the aim of reducing mortality.

Sample size calculation:

A minimum sample size of 1200 patients will provide 80% power to detect a relative risk reduction of approximately 30% in the treated group if the assumed composite rate (new requirement of intubation and / or death) in the control group is about 24%.

The ECLA PHRI COLCOVID Trial allows randomization to another trial, specifically patients included in the trial might be (or not) randomized to an antithrombotic strategy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Simple pragmatic randomized open controlled trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Local standard of care plus colchicine

Local standard of care plus colchicine (specific dosage schedule)

Group Type ACTIVE_COMPARATOR

Colchicine

Intervention Type DRUG

The colchicine dosage schedule will vary according to the following scenarios:

1. In patients not receiving Lopinavir/Ritonavir

* Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)
* The next day 0.5 mg bid for 14 days or until discharge.
2. In patients receiving Lopinavir/Ritonavir

* Loading dose of 0.5 mg (day 1)
* After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.
3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir

* Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.
* Continue with 0.5 mg every 72 hours for 14 days or until discharge.

Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.

Local standard of care

Intervention Type OTHER

Local standard of care for COVID-19 SARS moderate /high-risk patients

Local standard of care

Local standard of care for COVID-19 SARS moderate / high-risk patients

Group Type OTHER

Local standard of care

Intervention Type OTHER

Local standard of care for COVID-19 SARS moderate /high-risk patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colchicine

The colchicine dosage schedule will vary according to the following scenarios:

1. In patients not receiving Lopinavir/Ritonavir

* Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)
* The next day 0.5 mg bid for 14 days or until discharge.
2. In patients receiving Lopinavir/Ritonavir

* Loading dose of 0.5 mg (day 1)
* After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.
3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir

* Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.
* Continue with 0.5 mg every 72 hours for 14 days or until discharge.

Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.

Intervention Type DRUG

Local standard of care

Local standard of care for COVID-19 SARS moderate /high-risk patients

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Colchicina

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consented adults (age ≥18 years) and
* COVID-19 suspicious and
* Admitted to hospital or already in hospital and
* COVID-19 suggestive symptoms (fever or febrile equivalent, loss of smell and taste, fatigue, etc.) that may be present or absent at randomization time and
* SARS (severe acute respiratory syndrome)

* shortness of breath (dyspnea) or
* image of typical or atypical pneumonia or
* oxygen desaturation (SpO2 ≤ 93)

Exclusion Criteria

* Clear indication or contraindication for the use of colchicine
* Pregnant or breastfeeding female.
* Chronic renal disease with creatinine clearance \<15 ml/min/m2
* Negative PCR test for SARS-COV2

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No